PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024
SEONGNAM,
South Korea PharmaResearch, a leading pharmaceutical/medical device research
company, has announced its participation in the upcoming American Association
for Cancer Research (AACR) Annual Meeting 2024, scheduled from April 5th to
10th in San Diego, California. The company will unveil research findings
regarding its groundbreaking anticancer agent, PRD-101, through a poster
session.
The
presentations will cover diverse topics, including the efficacy demonstrated in
various patient-derived xenograft (PDX) animal models and the results of
in-depth characterization conducted by the National Cancer Institute’s
Nanotechnology Characterization Laboratory (NCL).
Presentation
Details
Poster Title:
Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical
study
Date and Time: Tuesday April 9, 1:30 AM - 5:00 PM PT
Session Category: Chemistry
Session
Title: Drug Delivery
Session
Location: Section 20
Poster
Board Number: 3
Abstract
number: 5735
About
PharmaResearch’s PRD-101
PRD-101
represents a significant advancement in cancer treatment, utilizing nucleotide
fragments produced through PharmaResearch's proprietary DNA optimization
technology (DOTTM) in nano-particle anticancer
formulations. Collaborative efforts between PharmaResearch and the University
of California Irvine (UCI) researchers, along with support from organizations
like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch
holds patents and exclusive license associated with PRD-101, marking a milestone
in the company's innovative endeavors.
Traditional
anticancer drugs often face limitations due to high toxicity, which restricts
patient eligibility and necessitates careful dosage management. PharmaResearch
anticipates that PRD-101 will address these unmet medical needs in anticancer
therapy. The company is committed to advancing quickly into clinical trials
based on promising safety and efficacy results obtained from preclinical
studies.
About
PharmaResearch
PharmaResearch
is a pioneering biopharmaceutical company dedicated to enhancing the quality of
life for humanity through regenerative medicine. With a diverse portfolio
encompassing medicines, medical devices, cosmetics, and supplements,
PharmaResearch focuses on leveraging its core ingredients, DOTTM
PDRN and DOTTM PN. These active tissue regenerative substances are
powered by DOTTM, an exclusive DNA fragments optimization technology
safeguarded by a suite of patents. PharmaResearch is located in Seongnam, South
Korea, and its US subsidiary, PharmaResarch USA is located in Costa Mesa,
Califrornia, US.
PharmaResearch's
participation in the AACR Annual Meeting underscores its dedication to
pioneering advancements in cancer research and treatment, ultimately aiming to
improve patient outcomes and quality of life.
For more information about PharmaResearch and its innovative initiatives, visit http://pharmaresearch.co.kr/en/ and connect with us on LinkedIn.